MedTrace Logo

Japan Dose Regimen Study of AZD1656 in Japanese Type 2 Diabetes Mellitus Patients

NCT01152385 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 224

Last updated 2012-08-27

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to compare the effect on glucose control of 3 different AZD1656 dosing regimens with placebo in Japanese type 2 diabetes mellitus (T2DM) patients, as evaluated by the change in HbA1c from baseline to the end of treatment at 4 months.

Conditions

Interventions

DRUG

AZD1656

Oral tablet administered twice daily during 4 months

DRUG

Placebo

administered twice daily during 4 months

Sponsors & Collaborators

Principal Investigators

  • Maria Leonsson-Zachrisson · AstraZeneca

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-05-31
Primary Completion
2011-05-31
Completion
2011-05-31

Countries

  • Japan

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01152385 on ClinicalTrials.gov